Pictor Debuts New PictImager® at ADLM 2026 to Make Targeted Protein Analysis More Practical
Beta-site engagement begins as Pictor introduces an integrated 96-well workflow designed for scalable targeted protein analysis in research laboratories. CARLSBAD, Calif., July 27, 2026 /PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic platform company, today announced the public debut of its next-generation high-resolution platform at ADLM 2026, highlighted by the...
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
TAIPEI, July 27, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today reaffirmed its strategic focus on pursuing global licensing partnerships to address the growing medical needs in the urology sector. Building upon the momentum of its recent participation...
Waters Launches Industry’s Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, cancer assessment, and toxicology. Offers 5x greater sensitivity vs. in-class instruments with lower detection limits in smaller sample volumes, introducing a step-change in analytical performance for complex biological matrices. Up to six-fold...
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX:3696), a clinical-stage, generative AI-driven drug discovery company, today announced that first-in-human...
Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
CHENGDU, China, July 27, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for its novel dual-payload...
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
Hospitals, clinics, academia and industry join a collaborative ecosystem designed to advance trusted, nationally grounded healthcare AI JAKARTA, Indonesia, July 27, 2026 /PRNewswire/ -- PT Articura Tech Indonesia ("Articura") today announced the foundation of its Sovereign Healthcare AI Platform, bringing together institutions across clinical care, academia, research and industry to support the responsible development of healthcare AI for...
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model.-Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will be submitted to the U.S. Food and Drug Administration (FDA) via a biologics license application (BLA). HONG KONG, July 27, 2026 /PRNewswire/...
Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over time Fast-onset and potent itch relief was observed as early as Day 1 after the first dose alongside robust and durable suppression of Type 2 inflammatory biomarkers Favorable safety, extended...
Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with China National Pharmaceutical Group Co., Ltd....
3Shape’s TRIOS MOVE Pro Scanner Cart Wins Red Dot 2026 Design Award
COPENHAGEN, Denmark, July 27, 2026 /PRNewswire/ -- 3Shape, a global innovator in digital dentistry with market-leading intraoral (IOS) scanners, has received this year's 2026 Red Dot Award for its TRIOS MOVE Pro Scanner Cart. The Red Dot Jury posted the following statement: 'The system architecture of TRIOS MOVE Pro combines mobility, ergonomic adaptability, and digital visualization, supporting flexible...
